RecruitingNot applicableNCT06659458
Official study title

Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients

Study summary

EGFR gene mutations are some of the most commonly occurring mutations in non-small cell lung cancer. Investigators have developed a DNA instability model that estimates a risk score to assess the likelihood of an individual acquiring a cancer-linked mutation. The aim of this study is to collect blood from both those diagnosed with EGFR positive lung cancer and healthy individuals, evaluate their gene sequence surrounding the EGFR landscape and use the cancer positive and healthy sequences to validate the risk assessment model, which may one day be used to provide insight on susceptibility of getting EGFR positive lung cancer or potentially other cancer types.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedblood draw and Gene sequencing

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · EGFR

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Mar 20, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Our Lady of the Lake Hospital

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Our Lady of the Lake Hospital
Interventions being studied
Other: blood draw; Other: Gene sequencing
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • 18-100 years old
  • Biologically born female
  • Diagnosed with EGFR positive lung cancer (Arm 1-Cancer group)
  • No cancer diagnosis (Arm 2-health control)
Reasons someone may not be able to joinExclusion criteria
  • less than 18 years of age
  • Biologically born male
  • Incarcerated at the time of participation

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Our Lady of the Lake Regional Medical CenterBaton Rouge, Louisiana

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 20, 2025. Always confirm current availability with the study team.

View original record ↗